N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=20 Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=36 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Phase 3 N=163 Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
Breast Cancer · Melanoma
Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes
Phase 3 N=1,047 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
Phase 2 N=93 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
N/A N=14 Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=114 Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Cancer
Primary: Cohort 1 - NaF PET/CT vs 99mTc-MDP Bone Scintigraphy — 10; 0; 0 Participants
Phase 1 N=20 Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8 · Invasive Breast Lobular Carcinoma · Metastatic Breast Lobular Carcinoma
Primary: Verified Detection Rate for Metastasis — 5.9; 5.5 SUVMax
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Phase 2 N=32 Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Phase 2 N=27 Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Phase 2 N=8 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Kidney Cancer · Melanoma (Skin) · Metastatic Cancer
Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants
N/A N=22 Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA
Cerebral Metastases
Primary: Quantitative Measurement of [18F]FPIA Uptake Within the Cerebral Metastases of Treatment naïve Patients. — 1.54; 1.47; 1.48 SUV_max (kBq/L/kBq/g)
Phase 2 N=43 Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Prostate Cancer · Bladder Cancer · Kidney Cancer
Primary: Percentage Change (From Baseline to 24 Hours) Between Metastatic and Benign Nodes — -33.6; -46.9 Percentage Change
Phase 2 N=28 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Phase 2 N=40 Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Phase 2 N=17 Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants